Detalhe da pesquisa
1.
Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate.
Cell
; 158(4): 916-928, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-25126794
2.
Identification of covalent fragment inhibitors for Plasmodium falciparum UCHL3 with anti-malarial efficacy.
Bioorg Med Chem Lett
; 94: 129458, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37634761
3.
Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.
PLoS Pathog
; 15(6): e1007722, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31170268
4.
Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors.
J Am Chem Soc
; 140(36): 11424-11437, 2018 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30107725
5.
CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs.
Mol Microbiol
; 101(3): 381-93, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27073104
6.
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.
PLoS Med
; 13(10): e1002138, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27701420
7.
UV-triggered affinity capture identifies interactions between the Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) and antimalarial agents in live parasitized cells.
J Biol Chem
; 288(31): 22576-83, 2013 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23754276
8.
High-content imaging as a tool to quantify and characterize malaria parasites.
Cell Rep Methods
; 3(7): 100516, 2023 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37533635
9.
Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome.
Cell Chem Biol
; 30(5): 470-485.e6, 2023 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36963402
10.
TRAM1 is involved in disposal of ER membrane degradation substrates.
Exp Cell Res
; 316(13): 2113-22, 2010 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20430023
11.
A Proteasome Mutation Sensitizes P. falciparum Cam3.II K13C580Y Parasites to DHA and OZ439.
ACS Infect Dis
; 7(7): 1923-1931, 2021 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33971094
12.
Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications.
ACS Pharmacol Transl Sci
; 4(2): 613-623, 2021 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33855275
13.
Animal models for SARS-CoV-2 research: A comprehensive literature review.
Transbound Emerg Dis
; 68(4): 1868-1885, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33128861
14.
Plasmodium falciparum Artemisinin Resistance: The Effect of Heme, Protein Damage, and Parasite Cell Stress Response.
ACS Infect Dis
; 6(7): 1599-1614, 2020 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32324369
15.
Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19).
J Mol Med (Berl)
; 98(10): 1369-1383, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32808094
16.
Plasmodium falciparum In Vitro Drug Resistance Selections and Gene Editing.
Methods Mol Biol
; 2013: 123-140, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31267498
17.
Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265.
ACS Infect Dis
; 5(1): 90-101, 2019 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30375858
18.
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study.
Lancet Infect Dis
; 18(8): 874-883, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29909069
19.
Protein Degradation Systems as Antimalarial Therapeutic Targets.
Trends Parasitol
; 33(9): 731-743, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28688800
20.
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
Lancet Infect Dis
; 17(6): 626-635, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28363636